GlassScriptPhysician profile
Ryan Kent Rader
NPI 1407389455
$6,645.94
in general payments reported to CMS, 2019-2025
17 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.00 · 2022: $619 · 2023: $671 · 2024: $3,215 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,928 · Food and Beverage: $1,057 · Education: $11.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,927.50 |
| Food and Beverage | $1,057.23 |
| Education | $11.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,908.36 | 2024-2025 | |
| Gilead Sciences, INC. | $1,180.02 | 2023-2025 | Trodelvy |
| Foundation Medicine, INC. | $445.55 | 2022-2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Stemline Therapeutics INC. | $234.93 | 2023-2025 | Orserdu |
| Tactile Systems Technology INC | $124.00 | 2022 | |
| Merck Sharp & Dohme LLC | $119.36 | 2022-2024 | Keytruda |
| Incyte Corporation | $113.35 | 2023 | Jakafi |
| Myriad Genetic Laboratories, INC. | $96.32 | 2025 | Myrisk |
| Celgene Corporation | $77.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $77.39 | 2022 | |
| Pfizer INC. | $67.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $54.84 | 2021-2023 | |
| Genzyme Corporation | $41.28 | 2022 | |
| G1 Therapeutics, INC. | $41.02 | 2022 | |
| Glaxosmithkline, LLC. | $24.94 | 2025 | Ojjaara |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.36 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $16.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.